Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: A comparison of 2 sequentially treated cohorts

American Journal of Kidney Diseases

Volumn 62, Issue 4, 2013, Pages 789-795

  Tseng, Po Lin ^a   Chen, Te Chuan ^a   Chien, Yu Shu ^a   Hung, Chao Hung ^a   Yen, Yi Hao ^a   Chang, Kuo Chin ^a   Tsai, Ming Chao ^a   Lin, Ming Tsung ^a   Lee, Chien Te ^a   Shen, Chien Heng ^b   Hu, Tsung Hui ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Chronic hepatitis C; hemodialysis; interleukin 28B; pegylated interferon and ribavirin combination therapy; sustained virologic response

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COUGHING; DERMATITIS; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GENOTYPE; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSOMNIA; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; RECURRENCE RISK; SIDE EFFECT; SUBCUTANEOUS IMMUNOTHERAPY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT WITHDRAWAL; VOMITING;

CHRONIC HEPATITIS C; HEMODIALYSIS; INTERLEUKIN 28B; PEGYLATED INTERFERON AND RIBAVIRIN COMBINATION THERAPY; SUSTAINED VIROLOGIC RESPONSE;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RENAL DIALYSIS; RIBAVIRIN;

EID: 84884534937     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2013.03.037     Document Type: Article

References (33)

1. F. Fabrizi, F.F. Poordad, P. Martin Hepatitis C infection and the patient with end-stage renal disease Hepatology 36 1 2002 3 10
2. P. Maisonneuve, L. Agodoa, R. Gellert Cancer in patients on dialysis for end-stage renal disease: an international collaborative study Lancet 354 9173 1999 93 99
3. E. Nakayama, T. Akiba, F. Marumo, C. Sato Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy J Am Soc Nephrol 11 10 2000 1896 1902
4. F. Fabrizi, B. Takkouche, G. Lunghi, V. Dixit, P. Messa, P. Martin The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies J Viral Hepat 14 10 2007 697 703
5. A. Bruchfeld, H. Wilczek, C.G. Elinder Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation Transplantation 78 5 2004 745 750
6. P. Mathurin, C. Mouquet, T. Poynard Impact of hepatitis B and C virus on kidney transplantation outcome Hepatology 29 1 1999 257 263
7. I.M. Mahmoud, A.F. Elhabashi, E. Elsawy, A.A. El-Husseini, G.E. Sheha, M.A. Sobh The impact of hepatitis C virus viremia on renal graft and patient survival: a 9-year prospective study Am J Kidney Dis 43 1 2004 131 139
8. F. Fabrizi, G. Lunghi, V. Dixit, P. Martin Meta-analysis: anti-viral therapy of hepatitis C virus-related liver disease in renal transplant patients Aliment Pharmacol Ther 24 10 2006 1413 1422
9. M.G. Ghany, D.B. Strader, D.L. Thomas, L.B. Seeff Diagnosis, management, and treatment of hepatitis C: an update Hepatology 49 4 2009 1335 1374
10. A. Craxì, J.M. Pawlotsky, H. Wedemeyer EASL Clinical Practice Guidelines: management of hepatitis C virus infection J Hepatol 55 2 2011 245 264
11. J.H. Hoofnagle, L.B. Seeff Peginterferon and ribavirin for chronic hepatitis C N Engl J Med 355 23 2006 2444 2451
12. M. Rendina, A. Schena, N.M. Castellaneta The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant J Hepatol 46 5 2007 768 774
13. C.H. Liu, C.C. Liang, C.J. Liu Pegylated interferon alpha-2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy Gut 58 2 2009 314 316
14. W. Hakim, S. Sheikh, I. Inayat HCV response in patients with end stage renal disease treated with combination pegylated interferon alpha-2a and ribavirin J Clin Gastroenterol 43 5 2009 477 481
15. A. Bruchfeld, K. Lindahl, O. Reichard, T. Carlsson, R. Schvarcz Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients J Viral Hepat 13 5 2006 316 321
16. D. Carriero, F. Fabrizi, A.J. Uriel, J. Park, P. Martin, D.T. Dieterich Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin Int J Artif Organs 31 4 2008 295 302
17. R. van Leusen, R.P. Adang, R.A. de Vries Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C Nephrol Dial Transplant 23 2 2008 721 725
18. N. Esforzado, J.M. Campistol Treatment of hepatitis C in dialysis patients Contrib Nephrol 176 2012 54 65
19. C.H. Liu, J.H. Kao Treatment of hepatitis C virus infection in patients with end-stage renal disease J Gastroenterol Hepatol 26 2 2011 228 239
20. F. Fabrizi, V. Dixit, P. Martin, P. Messa Combined antiviral therapy of hepatitis C virus in dialysis patients: meta-analysis of clinical trials J Viral Hepat 18 7 2011 e263 e269
21. Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease Kidney Int Suppl 109 2008 S1 S99
22. F. Fabrizi, V. Dixit, P. Messa, P. Martin Pegylated interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials J Med Virol 82 5 2010 768 775
23. F. Fabrizi, S.V. Ganeshan, G. Lunghi, P. Messa, P. Martin Antiviral therapy of hepatitis C in chronic kidney diseases: meta-analysis of controlled clinical trials J Viral Hepat 15 8 2008 600 606
24. C.E. Gordon, K. Uhlig, J. Lau, C.H. Schmid, A.S. Levey, J.B. Wong Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms Am J Kidney Dis 51 2 2008 263 277
25. C.H. Liu, C.C. Liang, J.W. Lin Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study Gut 57 4 2008 525 530
26. R. Bruno, P. Sacchi, V. Ciappina Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis C: a randomized, controlled study Antivir Ther 9 4 2004 491 497
27. G. Barril, J.A. Quiroga, P. Sanz, F. Rodriguez-Salvanes, R. Selgas, V. Carreno Pegylated interferon-alpha2a kinetics during experimental haemodialysis: impact of permeability and pore size of dialysers Aliment Pharmacol Ther 20 1 2004 37 44
28. M. Espinosa, M.D. Arenas, M.D. Aumente Anemia associated with pegylated interferon-alpha2a and alpha2b therapy in hemodialysis patients Clin Nephrol 67 6 2007 366 373
29. M. Silva, J. Poo, F. Wagner A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE) J Hepatol 45 2 2006 204 213
30. M.W. Russo, R. Ghalib, S. Sigal, V. Joshi Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C Nephrol Dial Transplant 21 2 2006 437 443
31. S.S. Tan, M.R. Abu Hassan, A. Abdullah, B.P. Ooi, T. Korompis, M.I. Merican Safety and efficacy of an escalating dose regimen of pegylated interferon alpha-2b in the treatment of haemodialysis patients with chronic hepatitis C J Viral Hepat 17 6 2010 410 418
32. D.N. Amarapurkar, N.D. Patel, A.L. Kirpalani Monotherapy with peginterferon alpha-2b {12 kDa} for chronic hepatitis C infection in patients undergoing haemodialysis Trop Gastroenterol 28 1 2007 16 18
33. B.E. Annicchiarico, M. Siciliano Pegylated interferon-alpha 2b monotherapy for haemodialysis patients with chronic hepatitis C Aliment Pharmacol Ther 20 1 2004 123 124